This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blank, M Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Blank, M Articles by Shoenfeld, Y Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

TNF DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome

Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel

I Krause

Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel

G Wildbaum

Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

N Karin

Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Y Shoenfeld

Center for Autoimmune diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, Israel, shoenfel{at}post.tau.ac.il

Naked DNA encoding TNFa was introduced to BALB/c mice with experimental antiphospholipid syndrome (APS) induced by b2GPI. Administration of naked DNA encoding TNFa resulted in the generation of immunological memory to its gene product, associated with elevated circulating anti-TNFa antibodies. Enriched IgG fraction of the mouse anti-TNFa was biologically active since it prevented endothelial cell activation by TNFa, e.g., inhibition of monocyte adhesion to activated endothelial cells (HUVEC). Mice immunized with b2GPI, vaccinated with TNFa DNA at an early stage of disease development, showed decreased titres of circulating anti-b2GPI antibodies as compared to the group of mice vaccinated with a control naked DNA. The reduction of anti-phospholipid antibody production was followed by amelioration of the foetal loss, increased platelet count to normal values as well as normalization of the prolonged aPTT. APS mice which were introduced to the TNFa DNA vector at a later stage of the disease development, showed less improvement in their clinical manifestations. The current study suggests a way in which a DNA vaccine can be employed for induction of a protective immunity in experimental APS.

Key Words: anti-ß2glycoprotein I autoimmunity • antiphospholipid syndrome • DNA vaccination • tumor necrosis factor

Lupus, Vol. 12, No. 7, 546-549 (2003)
DOI: 10.1191/0961203303lu399oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Shoenfeld, P. L. Meroni, and R. Cervera Antiphospholipid syndrome dilemmas still to be solved: 2008 status Ann Rheum Dis, April 1, 2008; 67(4): 438 - 442. [Full Text] [PDF]

				D. Neumann, T. Tschernig, D. Popa, A. Schmiedl, G. P. de Lema, K. Resch, and M. U. Martin Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: synergistic effect on autoimmune symptoms Int. Immunol., December 1, 2006; 18(12): 1779 - 1787. [Abstract] [Full Text] [PDF]

				R. Goldberg, Y. Zohar, G. Wildbaum, Y. Geron, G. Maor, and N. Karin Suppression of Ongoing Experimental Autoimmune Encephalomyelitis by Neutralizing the Function of the p28 Subunit of IL-27 J. Immunol., November 15, 2004; 173(10): 6465 - 6471. [Abstract] [Full Text] [PDF]

				R. Goldberg, G. Wildbaum, Y. Zohar, G. Maor, and N. Karin Suppression of Ongoing Adjuvant-Induced Arthritis by Neutralizing the Function of the p28 Subunit of IL-27 J. Immunol., July 15, 2004; 173(2): 1171 - 1178. [Abstract] [Full Text] [PDF]